Envoy Medical, Inc. COCHW

FY2025 · ended Dec 31, 2025 · Revenue $241,000, +7.1% YoY · Filed Mar 23, 2026

Envoy Medical, Inc. (COCH) files with the SEC under industry code 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $241,000 and a net loss of $23.8 million. Free cash flow was -$18.4 million.

Revenue (TTM)
$231,000
+11.1% vs year-ago TTM
Net income (TTM)
$-20.85M
+4.3% vs year-ago TTM
Operating cash flow (TTM)
$-22.23M
-26.3% vs year-ago TTM
Free cash flow (TTM)
$-22.44M
-23.7% vs year-ago TTM
EPS (TTM)
$-0.91
+79.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
76.88M
+260.5% vs prior year
Net cash
$2.82M
FY 2025
Operating margin
-10343.3%
FY 2026

Company profile

Industry
Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
Listed as
COCH (Nasdaq), COCHW (Nasdaq)
Fiscal year ends
December 31
Headquarters
White Bear Lake, MN
SEC filer status
, Emerging growth company
SEC CIK
1840877
Former names
Anzu Special Acquisition Corp I (until Sep 29, 2023)

Other Orthopedic, Prosthetic & Surgical Appliances & Supplies companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

Line
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
Revenue
$241,000
$225,000
$316,000
—
—
Operating income
-$22.3M
-$19.3M
-$18.4M
-$8.7M
-$5.2M
Net income
-$23.8M
-$20.8M
-$29.9M
-$15.9M
-$251,633
Diluted EPS
-$1.23
-$1.49
-$2.54
—
—
Operating cash flow
-$18.2M
-$17.9M
-$17.1M
-$8.8M
-$3.2M
Free cash flow
-$18.4M
-$18.9M
-$17.2M
—
—
Total assets
$8.6M
$11.5M
$8.3M
$2.6M
$426.9M
Total liabilities
$20.3M
$30.4M
$10.0M
$38.8M
$38.6M
Stockholders' equity
-$12.2M
-$18.8M
-$1.8M
-$36.2M
-$45.0M
Cash and investments
$3.7M
$5.5M
$4.2M
$183,000
$149,845
Total debt
$919,000
$945,000
$562,000
—
—

Recent SEC filings

Recent SEC filings
Form Description Filed Period
8-K Current report
Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
Oct 27, 2026 Oct 23, 2026
8-K Current report
Shareholder vote results
Oct 16, 2026 Oct 12, 2026
8-K Current report
Other events
Oct 7, 2026 Oct 6, 2026
8-K Current report
Officer or director change
Aug 27, 2026 Aug 24, 2026
8-K Current report
Results of operations
Aug 10, 2026 Aug 10, 2026
10-Q Quarterly report Aug 10, 2026 Jun 30, 2026

Source: SEC EDGAR filings. This is company-reported data, not investment advice.